Apr 16, 2026
Robert Schickel, Chief Executive Officer at NUAgo Therapeutics, is developing a cancer therapy using short RNAs to target and disrupt interconnected survival genes in cancer cells. The therapy has been shown to be non-toxic to healthy cells, which have high levels of microRNAs, whereas cancer cells downregulate...
Apr 16, 2026
Robert Schickel, Chief Executive Officer at NUAgo Therapeutics, is developing a cancer therapy using short RNAs to target and disrupt interconnected survival genes in cancer cells. The therapy has been shown to be non-toxic to healthy cells, which have high levels of microRNAs, whereas cancer cells downregulate...
Apr 16, 2026
Dr. Babak Saboury, Chief Scientific and Innovation Officer and Physician Founder of United Theranostics, discusses the emergence of nuclear oncology as the fourth pillar of cancer care. United Theranostics is combining advanced molecular imaging and radiopharmaceutical therapies to identify a cancer cell's unique...
Apr 16, 2026
Dr. Babak Saboury, Chief Scientific and Innovation Officer and Physician Founder of United Theranostics, discusses the emergence of nuclear oncology as the fourth pillar of cancer care. United Theranostics is combining advanced molecular imaging and radiopharmaceutical therapies to identify a cancer cell's unique...
Apr 15, 2026
Shaun Bagai, CEO of RenovoRx, has designed a drug-delivery platform to treat hard-to-reach chemo-resistant tumors such as pancreatic cancer by delivering chemotherapy directly to the tumor site. The RenovoCath device increases the drug concentration in the tumor while significantly reducing systemic toxicities and...